Skip to main content

Table 1 Patients´ demographic and clinical characteristics

From: Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain

Characteristic Value (n = 181)
Median age (range), years 71.4 (62.2–79.0)
Gender, n (%)
 Male 69 (38.1)
 Female 112 (61.9)
Race, n (%)
 Caucasian 178 (98.3)
 Asian 3 (1.7)
Smoking history, n (%)
 Former smoker 53 (30.3)
 Current smoker 26 (14.9)
 Never smoker 96 (54.9)
ECOG PS at diagnosis of advanced disease, n (%)
 0 46 (27.7)
 1 87 (52.4)
 2 26 (15.7)
 3 7 (8.1)
Tumor histology, n (%)
 Adenocarcinoma 161 (89.0)
 Squamous cell carcinoma 9 (5.0)
 Large cell carcinoma 5 (2.8)
 Adenosquamous cell carcinoma 2 (1.1)
 Carcinoma NOS 4 (2.2)
Clinical stage at diagnosis, n (%)
 IIIA 8 (4.4)
 IIIB 7 (3.9)
 IV 159 (87.8)
 Othera 7 (4)
Median number of metastatic sites (range) 2.0 (1.0–3.0)
Metastases location, n (%)b
 Lung 80 (45.7)
 Bone 75 (42.9)
 Pleura 50 (28.6)
 Lymph nodes 45 (25.7)
 Pleural effusion 30 (17.1)
 CNS 25 (14.3)
 Liver 25 (14.3)
  1. CNS Central nervous system, ECOG PS Eastern Cooperative Oncology Group Performance Status, NOS Not otherwise specified
  2. aOther clinical stages included: IA (one patient), IIA (5 patients) and IIB (one patient), bMetastatic locations presented in > 10% of patients